Throughout the month of October our aim is to highlight how the Randox clinical product range can be used to allow for the most accurate diagnosis and monitoring of cholesterol. As October is national cholesterol month, we want to raise awareness of the many dangers associated with cholesterol to better assess the risk of related complications.
Cholesterol plays a major role in atherosclerosis, the leading cause of cardiovascular disease (CVD). CVD is the leading global cause of death; accounting for over 17.9 million deaths in the USA in 2015. This figure is expected to grow to more than 23.6 million by 2030 despite the treatment of individuals with high LDL Cholesterol with statins. These statistics emphasise the urgent need for additional risk factors to be considered beyond traditional LDL Cholesterol measurement.
As a world leader in the field of cardiac risk and lipid testing, Randox are tackling the need for better cholesterol testing with our wide range of niche and high-performance assays including sdLDL Cholesterol, Lipoprotein (a) and HDL3 Cholesterol. In fact Randox is responsible for more than 15% of all cholesterol tests carried out across the globe. Read on to find out more about our complete range of clinical solutions.
Typically HDL Cholesterol, LDL Cholesterol and Triglycerides are measured to asses coronary heart disease (CAD) risk however these current methods only detect around 20% of all CAD patients. Recognising the need for more comprehensive risk assessment, the Randox range comprises sdLDL Cholesterol (sdLDL-C), HDL3 Cholesterol and Lipoprotein (a) amongst others. sdLDL-C is a vital risk marker for Myocardial Infarction (MI), research indicates that individuals with a predominance of sdLDL-C have 3-fold increased risk of MI. HDL3 Cholesterol on the other hand is widely accepted to have an inverse relationship with CVD risk, individuals with higher HDL3 Cholesterol levels are therefore at lower risk of developing CVD. Finally Lipoprotein (a) is an independent genetic risk factor for CVD with elevated levels often seen in patients with an otherwise normal lipid profile. Our complete range comprises 113 third party diagnostic reagents, applications are available for a variety of biochemistry analysers. To find out more about our cardiac risk assays click here.
Renowned for quality and reliability the RX series range of clinical chemistry analysers boasts a world leading test menu comprising both routine and novel lipid tests for accurate & reliable CVD risk assessment. In addition to novel assays such HDL3 Cholesterol, sdLDL Cholesterol, Lipoprotein (a) and Apolipoproteins, the RX series offers superior methodology for the accurate measurement of routine assays including HDL Cholesterol and LDL Cholesterol. Our superior direct clearance method for HDL cholesterol ensures a high degree of accuracy even with abnormal samples containing elevated levels of triglycerides. Similarly no sample pre-treatment is required with our direct clearance method for LDL Cholesterol resulting in less variability and excellent correlation to ultracentrifugation methods. To view the complete RX series test menu and discover more on our testing solutions click here.
Internal Quality Control
The Acusera Lipid controls offer testing for the complete lipid profile, including HDL, LDL and Total Cholesterol. Available in either liquid ready-to-use or lyophilised formats, our controls are ideal for laboratories of any size with flexible options available for each control. Our lipid controls are manufactured from 100% human serum, ensuring commutability, and therefore mimic the performance of a patient sample.
External Quality Assessment
Designed to monitor the performance of up to 7 lipid parameters, the RIQAS Lipid EQA programme is manufactured from 100% human serum ensuring commutability. With access to large peer groups and user-friendly reports supplied, RIQAS is the EQA scheme for your laboratory. Frequent reporting and flexible programme options are only two of many benefits associated with the RIQAS Lipid Programme.